Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.85−0.38 (-11.61%)
Close on Nov 17, 2026Market cap $234.24MP/E –Yield –
Lexeo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Lexeo Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$88.37M. For fiscal 2025 it was -$98.56M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$98.56M | – |
| FY2024 | Dec 31, 2024 | -$81.15M | – |
| FY2023 | Dec 31, 2023 | -$59.50M | – |
| FY2022 | Dec 31, 2022 | -$54.56M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.81M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.37M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.63M | – |
See a number that looks wrong?